June 19th, 2017
iVascular S.L.U. and Braile Biomedica are pleased to announce that they have entered into a joint-venture agreement, to develop innovative structural heart solutions.
The new entity, based in Barcelona (Spain), will be managed by Mrs. Patricia Braile, CEO of Braile Biomedica, as President, and by Mr. Lluis Duocastella, CEO of iVascular SLU, as CEO.
Primary focus is expected to be percutaneous aortic and mitral heart valves.
Mr Lluis Duocastella commented that, “the combination of established Braile high quality heart valve technology with iVascular unique know how and vertical integration, is an ideal configuration for bringing innovative solutions to the structural heart market”.
Mrs Patricia Braile also stated that “the complementary knowledge and technologies that the two companies have will generate a new concept in innovative products and processes “.
iVascular is a fast-growing company based in Barcelona that has developed exclusive technologies in a vertically integrated project to innovate and produce coronary and endovascular devices from basic raw materials to the final device or implant, including DCB, DES, SE nitinol stents, CoCr BMS, thrombus extractors and angioplasty balloons.
Braile Biomedica is a 40-year company based in Brazil with great experience on structural heart technologies. The company has a wide range of products for Cardiac Surgery, Interventional Cardiology, Vascular and Oncology fields. Braile is recognized as the most innovative company in Brazil and has a strong market participation inside Latin America and in developing countries.
